About Alpha-1 antitrypsin Drugs
Alpha-1 antitrypsin, also known as an alpha-1 protease inhibitor (A1PI), is a glycoprotein produced in the liver that helps in the inactivation of enzymes such as elastase, which break down proteins during inflammation induced by some injury. The decline in alpha-1 antitrypsin levels in the blood results in a rare genetic condition known as alpha-1 antitrypsin deficiency (AATD), which leads to the development of respiratory and liver diseases, and severe skin infections. The disease is passed on from parents to an offspring through mutated genes. Augmentation therapy using drugs derived from human plasma helps in maintaining levels of alpha-1 antitrypsin in the blood, helping in remission of the condition.
Technavio’s analysts forecast the global alpha-1 antitrypsin drugs market to grow at a CAGR of 35.42% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global alpha-1 antitrypsin drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded drugs and off-label drugs used for the symptomatic treatment of diseases occurring due to alpha-1 antitrypsin deficiency and other disorders.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Alpha-1 Antitrypsin Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Baxter International
• CSL Behring
• Grifols
• Kamada
Other prominent vendors
• Abeona Therapeutics
• Alnylam Pharmaceuticals
• Applied Genetic Technologies
• Arrowhead Research
• Baxalta
• Biogen
• Chiesi
• Curaxys
• Laboratoire français du Fractionnement et des Biotechnologies
• ProBioGen
• ProMetic Life Sciences
Market driver
• Improved diagnosis of alpha-1 antitrypsin deficiency (AATD)
• For a full, detailed list, view our report
Market challenge
• Limited plasma fractionation capacity
• For a full, detailed list, view our report
Market trend
• Increasing awareness about therapy
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Overview: Alpha-1 antitrypsin deficiency
• Pathophysiology
• Symptoms
• Diagnosis
• Management
PART 06: Overview: Alpha-1 antitrypsin drugs
• Components of blood plasma
• Regulation of plasma therapeutics
• Regulatory authorities
• Reimbursement
PART 07: Pipeline analysis
• D1-AAT
• B1-AAT
• C1-AAT
• rAAV1-CB-hAAT
• G1-AAT
• L1-AAT
• ARC-AAT
• AAT
• PTB-101 SDF Alpha
• ALN-AAT
PART 08: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 09: Market segmentation by route of administration
• Parenteral
• Inhalation
PART 10: Geographical segmentation
• Global alpha-1 antitrypsin drugs market by geography 2015-2020
• Alpha-1 antitrypsin drugs market in Americas
• Alpha-1 antitrypsin drugs market in EMEA
• Alpha-1 antitrypsin drugs market in APAC
PART 11: Market drivers
• Improved diagnosis of AATD
• Improving economic conditions
• Novel product opportunities
• High unmet needs
PART 12: Impact of drivers
PART 13: Market challenges
• Stringent regulations
• Limited plasma fractionation capacity
• Shortage of alpha-1 antitrypsin supply
• High cost of drugs
PART 14: Impact of drivers and challenges
PART 15: Market trends
• Strategic alliances and M&A
• Patient assistance programs
• Increasing awareness about therapy
PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• Baxter International
• CSL Behring
• Grifols
• Kamada
• Other prominent vendors
PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Common symptoms of AATD
Exhibit 03: Blood plasma composition
Exhibit 04: Plasma proteins composition by percentage share
Exhibit 05: Process of derivation of alpha-1 antitrypsin from plasma
Exhibit 06: Regulatory policies of plasma proteins therapeutics
Exhibit 07: Global alpha-1 antitrypsin drugs market: Products in pipeline
Exhibit 08: Global alpha-1 antitrypsin drugs market 2015-2020 ($ billions)
Exhibit 09: Five forces analysis
Exhibit 10: Global alpha-1 antitrypsin drugs market by geography 2015
Exhibit 11: Global alpha-1 antitrypsin drugs market by geography 2015-2020 ($ millions)
Exhibit 12: Alpha-1 antitrypsin drugs market in Americas 2015-2020 ($ millions)
Exhibit 13: Alpha-1 antitrypsin drugs market in EMEA 2015-2020 ($ millions)
Exhibit 14: Alpha-1 antitrypsin drugs market in APAC 2015-2020 ($ millions)
Exhibit 15: Global alpha-1 antitrypsin drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 16: Impact of drivers
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Global alpha-1 antitrypsin drugs market share analysis 2015
Exhibit 19: Baxter International: Business segmentation by revenue 2014
Exhibit 20: Baxter International: YoY growth rate and revenue of BioScience segment 2012-2014 ($ billions)
Exhibit 21: Baxter International: YoY growth rate and revenue of Glassia in the US, Canada, Australia and New Zealand 2012-2014 ($ millions)
Exhibit 22: Baxter International: Key takeaways
Exhibit 23: CSL Behring: Sales by area of therapy 2014
Exhibit 24: CSL Behring: Key takeaways
Exhibit 25: Grifols: YoY growth rate and revenue of bioscience segment 2012-2014 ($ billions)
Exhibit 26: Grifols: Key takeaways
Exhibit 27: Kamada: Business segmentation by revenue 2014
Exhibit 28: Kamada: YoY growth rate and revenue of Glassia (excluding US, Canada, Australia, and New Zealand) 2012-2014 ($ millions)
Exhibit 29: Kamada: Key takeaways
